STAA - STAAR Surgical Company

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
35.67
+0.96 (+2.77%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close34.71
Open34.85
Bid0.00 x 900
Ask0.00 x 1800
Day's Range34.78 - 36.00
52 Week Range21.70 - 41.65
Volume481,179
Avg. Volume333,601
Market Cap1.591B
Beta (3Y Monthly)2.33
PE Ratio (TTM)198.17
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
Press Releases
  • Business Wire

    STAAR Surgical to Host Investor and Analyst Day on November 8, 2019

    STAAR Surgical Company (STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, announced today that the Company will host an Investor and Analyst Day on Friday, November 8, 2019 in New York City at 8:30 a.m. EST. A webcast with accompanying slides of a presentation by Caren Mason, President and CEO of STAAR Surgical, and a presentation by Dr. Mark Packer will be available on the “Investors” page of the Company's website at https://www.staar.com/.

  • Business Wire

    STAAR Surgical Reports Third Quarter Results

    STAAR Surgical Company , a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today reported financial results for the third quarter ended September 27, 2019.

  • STAAR Surgical Celebrates Visual Freedom with Jorgensen Family
    Business Wire

    STAAR Surgical Celebrates Visual Freedom with Jorgensen Family

    STAAR Surgical Company (STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced that Dr. Jorn S. Jorgensen successfully implanted the Company’s EVO Visian ICL in his son, Jannik Jorgensen, during a live-streamed event which also celebrated the opening of EuroEyes’ newest clinic. Dr. Jorgensen is the founder, chairman, executive director and CEO of the EuroEyes clinic group, with clinics across Germany, Denmark and China.

  • Business Wire

    STAAR Surgical to Report Third Quarter Results on October 30, 2019

    STAAR Surgical Company (STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced that it will release financial results for the third quarter ended September 27, 2019 on Wednesday, October 30, 2019 after the market close. STAAR will host a conference call and webcast on Wednesday, October 30 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and operational progress. To access the conference call (Conference ID 7170127), please dial 855-765-5684 for domestic participants and 262-912-6252 for international participants.

  • ACCESSWIRE

    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of STAAR Surgical Company - STAA

    NEW YORK, NY / ACCESSWIRE / June 27, 2019 / Pomerantz LLP is investigating claims on behalf of investors of STAAR Surgical Company ("STAAR" or the "Company") (STAA). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. The investigation concerns whether STAAR and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

  • Business Wire

    STAAR Surgical Announces Expanded Recommended Diopter Range for EVO Visian ICL by Refractive Societies in Germany and Japan

    STAAR Surgical Company (STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced the leading refractive ophthalmic societies in Germany and Japan have increased the diopter range for recommended use of phakic refractive lenses, including the EVO Visian ICL, to -3.0 diopters from -6.0 diopters. A diopter is a unit of measure of the refractive power of a lens and correlates with the patient’s level of nearsightedness (myopia/distance vision needs).

  • Business Wire

    STAAR Surgical Reports First Quarter Results

    ICL Units Up 39% Resulting in Seventh Consecutive Quarter of Significant Growth

  • Business Wire

    STAAR Surgical Celebrates One Million Lens Milestone for Implantable Collamer® Lens (ICL)

    STAAR Surgical Company (STAA), a leading developer, manufacturer, and marketer of implantable lenses and companion delivery systems for the eye, today announced that more than one million Visian implantable Collamer lenses (ICLs) have been implanted globally. “We celebrate the Visian ICL one million lens milestone with our ophthalmology partners, clinicians, and patients who are elevating the ICL to the premium and primary solution for refractive based vision correction,” said Caren Mason, President and CEO of STAAR Surgical Company.

  • GlobeNewswire

    New Research: Key Drivers of Growth for Liberty Global, KKR Real Estate Finance Trust, AGCO, Model N, STAAR Surgical, and Mersana Therapeutics — Factors of Influence, Major Initiatives and Sustained Production

    NEW YORK, April 09, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Business Wire

    STAAR Surgical to Report First Quarter Results on May 1, 2019

    STAAR Surgical Company (STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced that it will release financial results for the first quarter ended March 29, 2019 on Wednesday, May 1, 2019 after the market close. STAAR will host a conference call and webcast on Wednesday, May 1 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and operational progress. To access the conference call (Conference ID 2299537), please dial 855-765-5684 for domestic participants and 262-912-6252 for international participants.

  • GlobeNewswire

    Glancy Prongay & Murray LLP Continues Investigation on Behalf of STAAR Surgical Company Investors (STAA)

    LOS ANGELES, March 01, 2019 -- Glancy Prongay & Murray LLP (“GPM”) continues its investigation on behalf of STAAR Surgical Company (NASDAQ: STAA) investors concerning the.